Teladoc Health Q1 Revenue Drops 2% as BetterHelp Segment Shrinks 9%, Reaffirms Outlook
TDOC sits 28% above its 52-week low of $4.4.
Summary
Teladoc Health reported a 2% year-over-year decline in Q1 revenue, with its BetterHelp segment revenue falling 9% and paying users decreasing. This continues a trend of revenue decrease and user metric decline previously noted in the company's 10-K. While the company slightly beat analyst expectations for Q1 revenue and adjusted EBITDA, and reaffirmed its full-year financial outlook, the ongoing contraction in its key BetterHelp segment presents a material challenge to its growth trajectory. Traders will monitor future reports for signs of stabilization or reversal in these core segments.
At the time of this announcement, TDOC was trading at $5.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.40 to $9.77. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.